Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma

Clinical and Developmental Immunology

Volumn 2012, Issue , 2012, Pages

  Jäkel, Clara E ^a   Hauser, Stefan ^a   Rogenhofer, Sebastian ^a   Müller, Stefan C ^a   Brossart, P ^a   Schmidt Wolf, Ingo G H ^a  

^a UNIVERSITY HOSPITAL BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 2;

ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CELL THERAPY; CHILL; CYTOKINE INDUCED KILLER CELL; DRUG MEGADOSE; DRUG TOLERABILITY; FEVER; HUMAN; IN VITRO STUDY; KIDNEY CARCINOMA; LOW DRUG DOSE; MONOTHERAPY; PERIPHERAL LYMPHOCYTE; PRIORITY JOURNAL; REVIEW; TREATMENT RESPONSE; ADOPTIVE IMMUNOTHERAPY; ANIMAL; IMMUNOLOGY; KIDNEY TUMOR; METHODOLOGY; MULTIMODALITY CANCER THERAPY;

ANIMALS; CARCINOMA, RENAL CELL; COMBINED MODALITY THERAPY; CYTOKINE-INDUCED KILLER CELLS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KIDNEY NEOPLASMS;

EID: 84870230209     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2012/473245     Document Type: Review

References (47)

1. Surveillance Epidemiology and End Results, SEER Stat Fact Sheets. National Cancer Institute, http://seer.cancer.gov/statfacts/html/kidrp.html
2. Garcia J. A., Rini B. I., Recent progress in the management of advanced renal cell carcinoma. CA-A Cancer Journal for Clinicians 2007 57 2 112 125 2-s2.0-34047222738 10.3322/canjclin.57.2.112 (Pubitemid 46535711)
3. American Cancer Society, Cancer Facts & Figures 2011 Atlanta, Ga, USA American Cancer Society
4. Harris D. T., Hormonal therapy and chemotherapy of renal cell carcinoma. Seminars in Oncology 1983 10 4 422 430 2-s2.0-0021013543 (Pubitemid 14158611)
5. Yang J. C., Sherry R. M., Steinberg S. M., Topalian S. L., Schwartzentruber D. J., Hwu P., Seipp C. A., Rogers-Freezer L., Morton K. E., White D. E., Liewehr D. J., Merino M. J., Rosenberg S. A., Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. Journal of Clinical Oncology 2003 21 16 3127 3132 2-s2.0-0042914703 10.1200/JCO.2003.02.122 (Pubitemid 46606294)
6. McDermott D. F., Regan M. M., Clark J. I., Flaherty L. E., Weiss G. R., Logan T. F., Kirkwood J. M., Gordon M. S., Sosman J. A., Ernstoff M. S., Tretter C. P. G., Urba W. J., Smith J. W., Margolin K. A., Mier J. W., Gollob J. A., Dutcher J. P., Atkins M. B., Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. Journal of Clinical Oncology 2005 23 1 133 141 2-s2.0-27144488811 10.1200/JCO.2005.03.206 (Pubitemid 41702632)
7. McDermott D. F., Immunotherapy of metastatic renal cell carcinoma. Cancer 2009 115 10 2298 2305 2-s2.0-65949102289 10.1002/cncr.24236
8. Rosenberg S. A., Interleukin 2 for patients with renal cancer. Nature Clinical Practice Oncology 2007 4 9, article 497 2-s2.0-34548453201 10.1038/ncponc0926 (Pubitemid 47351455)
9. Gollob J. A., Mier J. W., Veenstra K., McDermott D. F., Clancy D., Clancy M., Atkins M. B., Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN- γ induction is associated with clinical response. Clinical Cancer Research 2000 6 5 1678 1692 2-s2.0-0034103809 (Pubitemid 30305060)
10. Motzer R. J., Rakhit A., Schwartz L. H., Olencki T., Malone T. M., Sandstrom K., Nadeau R., Parmar H., Bukowski R., Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma. Clinical Cancer Research 1998 4 5 1183 1191 2-s2.0-0031924595 (Pubitemid 28213329)
11. Gollob J. A., Veenstra K. G., Parker R. A., Mier J. W., McDermott D. F., Clancy D., Tutin L., Koon H., Atkins M. B., Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma. Journal of Clinical Oncology 2003 21 13 2564 2573 2-s2.0-0038690512 10.1200/JCO.2003.12.119 (Pubitemid 46606339)
12. Haddad H., Rini B. I., Current treatment considerations in metastatic renal cell carcinoma. Current Treatment Options in Oncology 2012 13 2 212 229 2-s2.0-84863722477 10.1007/s11864-012-0182-8
13. Liu L., Zhang W., Qi X., Li H., Yu J., Wei S., Hao X., Ren X., Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma. Clinical Cancer Research 2012 18 6 1751 1759 2-s2.0-84863230396 10.1158/1078-0432.CCR-11-2442
14. Schmidt-Wolf I. G. H., Negrin R. S., Kiem H. P., Blume K. G., Weissman I. L., Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. Journal of Experimental Medicine 1991 174 1 139 149 2-s2.0-0025856106
15. + T cells. Cancer Immunology, Immunotherapy 2000 49 11 629 640 2-s2.0-0034948138 (Pubitemid 32204475)
16. Schmidt-Wolf I. G. H., Lefterova P., Mehta B. A., Fernandez L. P., Huhn D., Blume K. G., Weissman I. L., Negrin R. S., Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Experimental Hematology 1993 21 13 1673 1679 2-s2.0-0027860412 (Pubitemid 24223014)
17. Sievers E., Albers P., Schmidt-Wolf I. G. H., Märten A., Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma. Journal of Urology 2004 171 1 114 119 2-s2.0-0348109413 10.1097/01.ju.0000094803.60928.d7 (Pubitemid 37549104)
18. Franceschetti M., Pievani A., Borleri G., Vago L., Fleischhauer K., Golay J., Introna M., Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes. Experimental Hematology 2009 37 5 616 628 2-s2.0-64249142143 10.1016/j.exphem.2009.01.010
19. Schmidt-Wolf I. G. H., Lefterova P., Johnston V., Huhn D., Blume K. G., Negrin R. S., Propagation of large numbers of T cells with natural killer cell markers. British Journal of Haematology 1994 87 3 453 458 2-s2.0-0028301366 (Pubitemid 24230007)
20. + NK-T cells in the treatment of lymphoma. Biology of Blood and Marrow Transplantation 2001 7 10 532 542 2-s2.0-0035204217 (Pubitemid 33107563)
21. + T cells. Blood 2004 103 8 3065 3072 2-s2.0-1842526956 10.1182/blood-2003-06-2125 (Pubitemid 38451682)
22. Groh V., Rhinehart R., Secrist H., Bauer S., Grabstein K. H., Spies T., Broad tumor-associated expression and recognition by tumor-derived γ δ T cells of MICA and MICB. Proceedings of the National Academy of Sciences of the United States of America 1999 96 12 6879 6884 2-s2.0-0033536068 10.1073/pnas.96.12.6879 (Pubitemid 29274978)
23. Salih H. R., Antropius H., Gieseke F., Lutz S. Z., Kanz L., Rammensee H. G., Steinle A., Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood 2003 102 4 1389 1396 2-s2.0-0041737499 10.1182/blood-2003-01-0019 (Pubitemid 36988048)
24. Pende D., Rivera P., Marcenaro S., Chang C. C., Biassoni R., Conte R., Kubin M., Cosman D., Ferrone S., Moretta L., Moretta A., Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity. Cancer Research 2002 62 21 6178 6186 2-s2.0-0036829733 (Pubitemid 35244469)
25. Schmidt-Wolf I. G. H., Lefterova P., Johnston V., Scheffold C., Csipai M., Mehta B. A., Tsuruo T., Huhn D., Negrin R. S., Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells. Cellular Immunology 1996 169 1 85 90 2-s2.0-0029913888 10.1006/cimm.1996.0094
26. Mulé J. J., Shu S., Schwarz S. L., Rosenberg S. A., Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2. Science 1984 225 4669 1487 1489 2-s2.0-0021170244 (Pubitemid 14033135)
27. Rosenberg S. A., Lotze M. T., Muul L. M., Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. The New England Journal of Medicine 1985 313 23 1485 1492 2-s2.0-0022349817 (Pubitemid 16212345)
28. Lafreniere R., Rosenberg S. A., Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2. Cancer Research 1985 45 8 3735 3741 2-s2.0-0021969312 (Pubitemid 15226452)
29. Takahashi H., Nakada T., Puisieux I., Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice. Science 1993 259 5100 1460 1463 2-s2.0-0027506272 (Pubitemid 23101383)
30. Scheffold C., Brandt K., Johnston V., Lefterova P., Degen B., Schontube M., Huhn D., Neubauer A., Schmidt-Wolf I. G. H., Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia. Bone Marrow Transplantation 1995 15 1 33 39 2-s2.0-0028917966
31. Ren X., Yu J., Liu H., Zhang P., An X., Zhang N., Hao X., Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients. Cancer Biotherapy and Radiopharmaceuticals 2006 21 1 22 33 2-s2.0-33644896510 10.1089/cbr.2006.21.22
32. + cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. Journal of Immunology 1994 153 4 1687 1696 2-s2.0-0028103808 (Pubitemid 24251113)
33. Rosenberg S. A., Spiess P., Lafreniere R., A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science 1986 233 4770 1318 1321 2-s2.0-0022473607 (Pubitemid 16002234)
34. Whiteside T. L., Lotzova E., Herberman R. B., Human tumor-infiltrating lymphocytes and their characterization. Interleukin-2 and Killer Cells in Cancer 1990 Boca Raton, Fla, USA CRCPress 133 151
35. Yee C., Riddell S. R., Greenberg P. D., Prospects for adoptive T cell therapy. Current Opinion in Immunology 1997 9 5 702 708 2-s2.0-0030656557 10.1016/S0952-7915(97)80052-0 (Pubitemid 27485300)
36. Frost P., Caliliw R., Belldegrun A., Bonavida B., Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes. International Journal of Oncology 2003 22 2 431 437 2-s2.0-0042161880
37. Schmidt-Wolf I. G. H., Finke S., Trojaneck B., Denkena A., Lefterova P., Schwella N., Heuft H. G., Prange G., Korte M., Takeya M., Dorbic T., Neubauer A., Wittig B., Huhn D., Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma. British Journal of Cancer 1999 81 6 1009 1016 2-s2.0-0032698796 10.1038/sj.bjc.6690800 (Pubitemid 29516145)
38. Olioso P., Giancola R., Di Riti M., Contento A., Accorsi P., Iacone A., Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial. Hematological Oncology 2009 27 3 130 139 2-s2.0-67650360317 10.1002/hon.886
39. Therasse P., Arbuck S. G., Eisenhauer E. A., Wanders J., Kaplan R. S., Rubinstein L., Verweij J., Van Glabbeke M., Van Oosterom A. T., Christian M. C., Gwyther S. G., New guidelines to evaluate the response to treatment in solid tumors. Journal of the National Cancer Institute 2000 92 3 205 216 2-s2.0-0034594628 (Pubitemid 30099779)
40. Su X., Zhang L., Jin L., Ye J., Guan Z., Chen R., Guo T., Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma. Cancer Biotherapy and Radiopharmaceuticals 2010 25 4 465 470 2-s2.0-77956169022 10.1089/cbr.2010.0762
41. Lei K., Wang J., Jia Y., Xiong Y., Yuan Z., The effects of CIK cells on the treatment of renal cell carcinoma. Chinese-German Journal of Clinical Oncology 2009 8 6 346 348 2-s2.0-67650257561 10.1007/s10330-009-0040-8
42. Li X., Xu W., Cui J., Yang L., Ai J., Zhao W., Effect of CIK treatment on localized renal carcinoma patients after radical operation. China Research on Prevention and Treatment 2011 38 8 950 953
43. Wang H., Zhou F. J., Wang Q. J., Qin Z. K., Huang L. X., Liu Z. W., Han H., Li Y. Q., Chen S. P., Xia J. C., Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma-a report of ten cases. Ai Zheng 2006 25 5 625 630 2-s2.0-36849017520
44. + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients. Journal of Clinical Immunology 2007 27 3 317 326 2-s2.0-34249074132 10.1007/s10875-007-9076-0 (Pubitemid 46790817)
45. Lin G., Wang J., Lao X., Wang J., Li L., Li S., Zhang J., Dong Y., Chang A. E., Li Q., Li S., Interleukin-6 inhibits regulatory t cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells. Journal of Immunotherapy 2012 35 4 337 343 2-s2.0-84859882648 10.1097/CJI. 0b013e318255ada3
46. Hontscha C., Borck Y., Zhou H., Messmer D., Schmidt-Wolf I. G. H., Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC). Journal of Cancer Research and Clinical Oncology 2011 137 2 305 310 2-s2.0-78751628167 10.1007/s00432-010-0887-7
47. An Y., Li Y., Gao H., Zhang X., A Phase I/II Evaluation of Cytokine Induced Killer Cells Stimulated by DC(DCIK) Immunotherapy in Patients With Renal Cell Carcinoma. http://clinicaltrials.gov/ct2/show/NCT01240005